Triamcinolone Acetonide Injection Uses and Side Effects

Triamcinolone acetonide is a synthetic corticosteroid injected directly into joints, skin lesions, the eye, and other tissues to suppress inflammation at the site where it matters most. It has been a workhorse in medicine for decades, used for conditions ranging from knee osteoarthritis and keloid scars to diabetic macular edema and alopecia areata. Because the drug is deposited locally rather than taken by mouth, it can deliver high concentrations to a small area while limiting whole-body exposure, though “limiting” is not the same as “eliminating,” and the systemic effects of these injections are more significant than many patients realize.

What Triamcinolone Acetonide Injections Are Used For

The versatility of triamcinolone acetonide is one reason it shows up in so many different specialties. Orthopedic surgeons and rheumatologists inject it into arthritic knees, shoulders, and smaller joints. Dermatologists inject it into keloid and hypertrophic scars, cystic acne, and patches of hair loss. Ophthalmologists inject it into or around the eye for swelling caused by diabetes or uveitis. Pain management physicians use epidural injections for spinal inflammation. And allergists have occasionally used intramuscular injections for severe seasonal allergies, though that practice has fallen out of favor in many countries.

The drug works by entering cells and dialing down the production of inflammatory proteins. In practical terms, this means less swelling, less pain, and less immune-mediated tissue damage at the injection site. Because the crystalline suspension dissolves slowly, a single injection can suppress local inflammation for weeks to months, depending on the dose and location.

Knee Osteoarthritis and the Cartilage Question

Knee injections are probably the most common use of triamcinolone acetonide, and they come with a complicated track record. A two-year randomized trial published in JAMA compared patients receiving triamcinolone injections every three months with patients receiving saline injections. The triamcinolone group lost more cartilage over two years and did not report significantly less pain than the saline group.¹ That finding rattled the orthopedic community, because repeated steroid injections had been standard care for decades.

The cartilage concern is not unique to triamcinolone. A systematic review of corticosteroids and cartilage found dose-dependent harmful effects across multiple steroid types in both lab and animal studies, with significant cartilage damage appearing at higher cumulative doses.² Separately, lab work on human cartilage cells showed that triamcinolone acetonide was directly toxic to chondrocytes, the cells responsible for maintaining cartilage.³

Does this mean you should never get a knee injection? Not necessarily. Most clinicians now think of steroid injections as a short-term tool for flare-ups rather than a scheduled maintenance therapy. A multicenter trial found that even a lower 10 mg dose produced pain and quality-of-life improvements comparable to the standard 40 mg dose at 12 weeks, suggesting that less drug may accomplish the same goal with potentially less cartilage risk.⁴ A meta-analysis comparing different injectable steroids found triamcinolone performed slightly better than methylprednisolone in the very short term, though the advantage faded over time.⁵

Extended-Release Formulations

One of the more interesting developments in recent years is an extended-release version of triamcinolone acetonide designed specifically for knee osteoarthritis. The drug is embedded in tiny biodegradable microspheres that release it slowly over weeks, keeping the steroid concentrated in the joint longer while reducing how much spills into the bloodstream.

In a retrospective study of patients who had already failed standard steroid injections, the extended-release formulation provided roughly seven additional weeks of relief compared with the prior conventional injection.⁶ A pooled analysis of clinical trials found that among patients whose pain scores were consistently measured, about 28% of those receiving extended-release triamcinolone reported zero knee pain at 12 weeks, compared with roughly 8% of those receiving the conventional suspension.⁷

The extended-release version also appears gentler on blood sugar. In patients with type 2 diabetes, those receiving the extended-release formulation had smaller glucose spikes, spent more time in their target glucose range, and took much longer to reach high glucose levels compared with those getting the standard immediate-release injection.⁸ For anyone managing diabetes alongside joint pain, that difference matters.

Keloid and Hypertrophic Scars

Intralesional triamcinolone acetonide has been the go-to treatment for raised scars for a long time. The injections flatten keloids and hypertrophic scars by suppressing collagen production and shrinking the overactive fibroblasts that build up scar tissue. Response rates are high initially, with regression between 50% and 100% reported, but the recurrence rate is substantial: about a third of keloids return within a year, and roughly half return within five years.⁹

Triamcinolone works faster than alternatives like verapamil for scar reduction, but a systematic review and meta-analysis found that for medium- and long-term outcomes, combinations using 5-fluorouracil (5-FU) with or without triamcinolone may produce better results, particularly for scar height.¹⁰ In practice, many dermatologists now use triamcinolone as the initial treatment and add 5-FU or other agents for scars that do not respond adequately or that recur.

Alopecia Areata

For patchy hair loss caused by autoimmune alopecia areata, intralesional triamcinolone injections are considered first-line therapy, often alongside topical steroids or minoxidil.¹¹ The injections are given directly into the bald patches on the scalp, eyebrows, or beard using a fine needle, typically at four- to six-week intervals. Hair regrowth usually begins within a few weeks of the first session in responsive patients.

The treatment works best for limited patches. When alopecia areata involves more than about half the scalp, intralesional injections become impractical because the area requiring coverage is simply too large. The main local risk is temporary skin thinning (atrophy) at the injection sites, which usually resolves on its own once injections stop.

Ophthalmic Injections

Triamcinolone acetonide injected into or around the eye is used to treat diabetic macular edema, the swelling of the retina’s central area that blurs vision in people with diabetes. In one study of intravitreal injection, patients gained a median of 12 letters on a vision chart by three months, with retinal swelling dropping by about 28% over the same period.¹² Fluorescein angiography, which maps leaking blood vessels in the retina, has consistently shown reduced leakage after triamcinolone injection.¹³

Anti-VEGF drugs (like ranibizumab and aflibercept) have largely replaced triamcinolone as the first choice for diabetic macular edema in recent years, but triamcinolone has found a second life as a rescue option when anti-VEGF therapy stops working. A recent study found that switching to intravitreal triamcinolone after bevacizumab failure maintained improvements in retinal thickness through 12 months of follow-up.¹⁴

A newer delivery route, suprachoroidal injection, places the drug in the space between the choroid and the sclera rather than directly in the vitreous gel. In animal studies, this approach concentrated the drug in the back-of-the-eye tissues where it is needed while dramatically reducing exposure in the lens and other structures where it causes problems.¹⁵ This matters because the two biggest side effects of intravitreal triamcinolone are elevated eye pressure and cataracts. In one study, over half of eyes developed pressure above 21 mmHg after injection, appearing on average about seven to eight weeks later.¹⁶ Another found that about a third of eyes had pressure spikes above 24 mmHg, with roughly 16% of patients with natural lenses eventually needing cataract surgery.¹⁷ Suprachoroidal delivery shows promise for reducing these risks, though longer-term human data are still accumulating. A small pediatric uveitis study using the suprachoroidal route found that only one in ten eyes had a clinically significant pressure increase, and it was managed with drops alone.¹⁸

Blood Sugar Spikes in People with Diabetes

Even though the injection goes into a joint or skin lesion, enough triamcinolone gets absorbed into the bloodstream to raise blood sugar. In diabetic patients receiving hand and wrist injections, fasting blood glucose rose by an average of about 43 mg/dL on the first day after injection and about 17 mg/dL on day two before returning to baseline by day four.¹⁹ A controlled study of intra-articular knee injections found that blood sugar peaked around 24 to 33 hours after injection and took roughly two and a half to four days to normalize.²⁰

If you have diabetes, this does not mean you cannot receive a triamcinolone injection, but you should plan for it. Monitor your blood sugar more closely for the first three to four days, have a plan for adjusting your insulin or oral medications, and let both the injecting physician and your diabetes care team know. The extended-release formulation discussed earlier produces smaller spikes, so it is worth asking about if blood sugar management is a major concern for you.

Effects on the Body’s Cortisol System

Your adrenal glands normally produce cortisol under the direction of the brain’s hypothalamic-pituitary axis. When you receive an injection of synthetic corticosteroid, the brain detects the extra steroid and turns down its own production. After a single epidural triamcinolone injection, one study found that cortisol and the pituitary hormone ACTH both dropped dramatically within the first week. The pituitary’s response to stimulation recovered by about four weeks, but the adrenal glands’ ability to produce cortisol in response to that stimulation remained suppressed and did not fully recover until around 12 weeks.²¹ Animal studies of joint injections confirm the same pattern: cortisol and ACTH drop significantly within hours of injection.²²

For most adults getting an occasional injection, this suppression is temporary and clinically silent. But it becomes a real concern with repeated injections, high doses, or in children. A case series described three pediatric patients who developed outright Cushing’s syndrome, with weight gain, moon face, and growth suppression, after receiving triamcinolone acetonide injections. One child developed it after a single 40 mg hip injection. Symptoms appeared four to six weeks after injection and lasted four to six months.²³ Children have smaller body mass to dilute the drug and more sensitive hormonal axes, so the threshold for systemic effects is lower.

Skin and Soft Tissue Side Effects

When triamcinolone is injected into or near the skin, local side effects are relatively common. The most recognizable is skin atrophy: a visible depression or thinning at the injection site, sometimes with a change in skin color. A retrospective study cataloged the range of local reactions, including thinning, visible blood vessels (telangiectasias), lightening of the skin (hypopigmentation), and localized fat loss (panniculitis).²⁴ Occasionally the steroid tracks along the lymphatic vessels from the injection site, causing a branching pattern of lightened, thinned skin that extends well beyond where the needle was placed.²⁵ These changes are usually reversible over months, but they can be distressing, especially on visible areas like the face or hands, and in darker skin tones where hypopigmentation is more noticeable.

Tendon damage is a rarer but more serious concern. Triamcinolone suppresses tendon cell activity and reduces collagen production in a dose-dependent way, and case reports describe tendon rupture after injections near tendons, particularly in the hand.²⁶ The risk appears to rise with higher doses and more frequent injections.²⁷ A broad review of corticosteroid injection side effects lists tendon rupture alongside postinjection pain flares, skin changes, infection, and accelerated joint degeneration as recognized local complications.²⁸

Allergic Reactions and Excipient Sensitivity

True allergy to the triamcinolone molecule itself is exceedingly rare. When patients have immediate allergic reactions after a triamcinolone injection, the culprit is often not the steroid at all. A case series highlighted carboxymethylcellulose, a thickening agent used in the injectable suspension, as a hidden trigger for hypersensitivity reactions. Because clinicians do not routinely think to test for excipient allergies, affected patients are sometimes mislabeled as allergic to all corticosteroids, which unnecessarily limits their treatment options going forward.²⁹ If you have ever had a reaction to a triamcinolone injection, it is worth asking an allergist to test for the inactive ingredients specifically, rather than assuming the steroid itself is the problem.

Use in Veterinary Medicine

Triamcinolone acetonide is not only a human drug. It has been used for decades in equine practice for joint inflammation and osteoarthritis, and a randomized trial in 80 lame horses evaluated intra-articular triamcinolone alone versus triamcinolone combined with hyaluronate.³⁰ The same pharmacological principles apply: the crystalline depot dissolves slowly in the joint, suppressing inflammation for weeks. Veterinary research on triamcinolone actually informs human medicine as well, since animal joint studies can be more tightly controlled and provide tissue samples that would be impossible to obtain from human patients. The finding that systemic absorption is greater when the drug is injected inside a joint capsule compared with into the tissues surrounding a joint, for example, came from equine research and has implications for how clinicians think about dosing and systemic effects in people.³¹

How Many Injections Are Too Many

This is the question patients most want answered, and the honest answer is that there is no universally agreed-upon number. Traditional clinical guidelines have often suggested limiting joint injections to three or four per year, with a lifetime limit sometimes mentioned but rarely backed by strong evidence. The JAMA trial that found cartilage loss used injections every three months for two years, amounting to eight injections, which is more aggressive than most real-world practice. The cartilage data, the dose-dependent toxicity seen in lab studies, and the hormonal suppression data all point in the same direction: fewer injections and lower doses are preferable when they achieve adequate relief.

For scar treatment, many dermatologists space injections four to six weeks apart and reassess after three to four sessions. For alopecia areata, a similar interval is typical. In the eye, the frequency depends on how quickly the edema recurs and whether the patient can tolerate alternative therapies. In every case, the calculus is the same: the injection provides real, sometimes dramatic short-term benefit, but each one carries cumulative risks to the local tissue and, to a lesser degree, to systemic hormonal balance. The trend in the field is toward using the lowest effective dose, spacing injections as far apart as symptoms allow, and switching to non-steroidal alternatives when long-term management is needed.